Back to News
Market Impact: 0.25
Amgen says drug combo cuts risk of death by 58% in patients with aggressive lung cancer
Source: CNBC
Healthcare & Biotech
An Amgen drug, when added to an AstraZeneca immunotherapy, could significantly extend survival for patients with an aggressive form of lung cancer. The article provides no numerical survival data or further details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
AMGN0.75
AZN0.65
More News
- Biotech stocks are surging. How investors can play the new drug innovation boom
- IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER
- Perioperative IMFINZI® (durvalumab) plus neoadjuvant enfortumab vedotin reduced risk of recurrence by 49% and risk of death by 42% in muscle-invasive bladder cancer
- IMFINZI® (durvalumab) plus tarlatamab-dlle reduced the risk of death by 58% in 1st-line extensive-stage small cell lung cancer in the DeLLphi-305 Phase III trial
- Amgen's IMDELLTRA Cuts Death Risk 58% in Small-Cell Lung Cancer Study
- Amgen Inc. (AMGN) Presents at 2026 European Society for Medical Oncology (ESMO) Annual Congress Transcript